SCHEMBL1645441

SCHEMBL1645441

Cc1cc(C)nc(OCCNc2ccc(NC(=O)C(=O)c3c(-c4ccccc4)c(C)c4ccccn34)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
ALDH1A1 P00352 8/20 0.36
MAPT P10636 8/20 0.36
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
PPARG P37231 3/20 0.36
NCOR2 Q9Y618 3/20 0.36
KDM4E B2RXH2 3/20 0.36
NR2E3 Q9Y5X4 2/20 0.36
PABPC1 P11940 1/20 0.36
LMNA P02545 6/20 0.36
NPSR1 Q6W5P4 3/20 0.36
TDP1 Q9NUW8 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
HTT P42858 2/20 0.34
LTB4R Q15722 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1644580 0.91 MAPT (0.37) HCRTR1HCRTR2ALDH1A1MAPTMEN1
SCHEMBL1645439 0.88 ALDH1A1 (0.37) ALDH1A1MAPTMEN1KMT2APPARG
SCHEMBL1645910 0.84 LMNA (0.36) ALDH1A1MAPTMEN1KMT2APPARG
SCHEMBL1645908 0.84 ALDH1A1 (0.36) ALDH1A1MAPTMEN1KMT2APPARG
SCHEMBL4564049 0.83 LMNA (0.35) ALDH1A1MAPTMEN1KMT2APPARG
SCHEMBL1987586 0.81 HCRTR2 (0.40) HCRTR1HCRTR2ALDH1A1MAPTMEN1
SCHEMBL1646589 0.81 LMNA (0.42) HCRTR1HCRTR2ALDH1A1MAPTMEN1
SCHEMBL1645861 0.80 ALDH1A1 (0.35) ALDH1A1MAPTMEN1KMT2APPARG
SCHEMBL1646893 0.80 LMNA (0.35) ALDH1A1MAPTMEN1KMT2APPARG
SCHEMBL1646624 0.79 SMN1; SMN2 (0.41) HCRTR1HCRTR2ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 EP disclosed
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 EP disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 EP disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 HCRTR1 427/4885HCRTR2 1157/4885ALDH1A1 2813/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 HCRTR1 1146/4885HCRTR2 1096/4885ALDH1A1 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.